Raoof A - Search Results

1

Pharmacokinetics and pharmacodynamics of TMC207 and its N-desmethyl metabolite in a murine model of tuberculosis.

Rouan MC, Lounis N, Gevers T, Dillen L, Gilissen R, Raoof A, Andries K. Rouan MC, et al. Among authors: raoof a. Antimicrob Agents Chemother. 2012 Mar;56(3):1444-51. doi: 10.1128/AAC.00720-11. Epub 2011 Dec 12. Antimicrob Agents Chemother. 2012. PMID: 22155815 Free PMC article.

2

Real life juvenile toxicity case studies: the good, the bad and the ugly.

De Schaepdrijver L, Rouan MC, Raoof A, Bailey GP, De Zwart L, Monbaliu J, Coogan TP, Lammens L, Coussement W. De Schaepdrijver L, et al. Among authors: raoof a. Reprod Toxicol. 2008 Sep;26(1):54-5. doi: 10.1016/j.reprotox.2008.04.002. Epub 2008 Jun 2. Reprod Toxicol. 2008. PMID: 18514481

3

TMC310911, a novel human immunodeficiency virus type 1 protease inhibitor, shows in vitro an improved resistance profile and higher genetic barrier to resistance compared with current protease inhibitors.

Dierynck I, Van Marck H, Van Ginderen M, Jonckers TH, Nalam MN, Schiffer CA, Raoof A, Kraus G, Picchio G. Dierynck I, et al. Among authors: raoof a. Antimicrob Agents Chemother. 2011 Dec;55(12):5723-31. doi: 10.1128/AAC.00748-11. Epub 2011 Sep 6. Antimicrob Agents Chemother. 2011. PMID: 21896904 Free PMC article.

4

Clinical pharmacokinetics and pharmacodynamics of etravirine.

Schöller-Gyüre M, Kakuda TN, Raoof A, De Smedt G, Hoetelmans RM. Schöller-Gyüre M, et al. Among authors: raoof a. Clin Pharmacokinet. 2009;48(9):561-74. doi: 10.2165/10895940-000000000-00000. Clin Pharmacokinet. 2009. PMID: 19725591 Review.

5

Absorption, metabolism, and excretion of darunavir, a new protease inhibitor, administered alone and with low-dose ritonavir in healthy subjects.

Vermeir M, Lachau-Durand S, Mannens G, Cuyckens F, van Hoof B, Raoof A. Vermeir M, et al. Among authors: raoof a. Drug Metab Dispos. 2009 Apr;37(4):809-20. doi: 10.1124/dmd.108.024109. Epub 2009 Jan 8. Drug Metab Dispos. 2009. PMID: 19131522

6

Patient-centered drug discovery as the means to improved R&D productivity.

Raoof AA, Aerssens J. Raoof AA, et al. Drug Discov Today. 2015 Sep;20(9):1044-8. doi: 10.1016/j.drudis.2015.04.002. Epub 2015 Apr 20. Drug Discov Today. 2015. PMID: 25908579 No abstract available.

7

Oral bioavailability and multiple dose tolerability of an antisense oligonucleotide tablet formulated with sodium caprate.

Raoof AA, Chiu P, Ramtoola Z, Cumming IK, Teng C, Weinbach SP, Hardee GE, Levin AA, Geary RS. Raoof AA, et al. J Pharm Sci. 2004 Jun;93(6):1431-9. doi: 10.1002/jps.20051. J Pharm Sci. 2004. PMID: 15124202

8

In vivo assessment of intestinal, hepatic, and pulmonary first pass metabolism of propofol in the rat.

Raoof AA, Augustijns PF, Verbeeck RK. Raoof AA, et al. Pharm Res. 1996 Jun;13(6):891-5. doi: 10.1023/a:1016057229478. Pharm Res. 1996. PMID: 8792428

9

Propofol pharmacokinetics in children with biliary atresia.

Raoof AA, van Obbergh LJ, Verbeeck RK. Raoof AA, et al. Br J Anaesth. 1995 Jan;74(1):46-9. doi: 10.1093/bja/74.1.46. Br J Anaesth. 1995. PMID: 7880705 Free article.

10

Effect of sodium caprate on the intestinal absorption of two modified antisense oligonucleotides in pigs.

Raoof AA, Ramtoola Z, McKenna B, Yu RZ, Hardee G, Geary RS. Raoof AA, et al. Eur J Pharm Sci. 2002 Nov;17(3):131-8. doi: 10.1016/s0928-0987(02)00162-8. Eur J Pharm Sci. 2002. PMID: 12393140

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters